Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation

Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation

Background: Chronic myelomonocytic leukemia is a clonal hematological disorder with an inherent risk of transformation to acute myeloid leukemia. Recently, there has been exponential discovery of molecular abnormalities in patients with chronic myelomonocytic leukemia. Some of these mutations indepe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Emiko Kashima, Yuka Sugimoto, Keiki Nagaharu, Eiko Ohya, Makoto Ikejiri, Yasuyuki Watanabe, Shinichi Kageyama, Koji Oka, Isao Tawara
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Hematology
Subjects:	Chronic myelomonocytic leukemia blastic transformation venetoclax RUNX1 next-generation sequencing
Online Access:	https://www.tandfonline.com/doi/10.1080/16078454.2024.2392908
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dermatoscopic features of blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature
by: Daniel Argüello-Ruiz, et al.
Published: (2024-10-01)

AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA: AN EFFECTIVE AND MANAGEABLE APPROACH.
by: Pasquale Niscola
Published: (2014-02-01)

A RUNX1: RUNX1T1 AML with a simultaneous false positive KMT2A rearrangement: FISH interpretation pitfalls
by: Chi Zhang, et al.
Published: (2024-12-01)

Blastic plasmacytoid dendritic cell neoplasm of skin, a rare dermatohematologic malignancy—A case report
by: Ramtin Edjtemaei, et al.
Published: (2024-09-01)

Molecular profiling of acute myeloid leukemia with Runx1-Runx1t1 fusion
by: Magdy Elbordiny, et al.
Published: (2024-12-01)

“A Friend Among Strangers” or the Ambiguous Roles of Runx2
by: Kseniia Azarkina, et al.
Published: (2024-10-01)

The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID
by: Antonio Cristiano, et al.
Published: (2022-04-01)

Radiation Therapy for Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report and Review of the Literature
by: Masashi Taka, et al.
Published: (2024-11-01)

RUNX2 enhances bladder cancer progression by promoting glutamine metabolism
by: Zhigang Huang, et al.
Published: (2025-02-01)

RUNX1::CBFA2T2 rearranged acute myeloid leukemia transformed from JAK2 V617F mutated primary myelofibrosis
by: Lina Han, et al.
Published: (2024-12-01)

A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management
by: Elena Elli, et al.
Published: (2012-01-01)

A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management
by: Elena Elli, et al.
Published: (2012-03-01)

Unusual transformation from refractory anemia to chronic myelomonocytic leukemia: a case report.
by: Pasquale Niscola
Published: (2014-08-01)

Prognostic Significance and Treatment Response Associations of Genetic Mutations in Chronic Myelomonocytic Leukemia: A Retrospective Cohort Study
by: Jing Di, et al.
Published: (2024-10-01)

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations
by: Xin Wang, et al.
Published: (2024-12-01)

Brg1 and RUNX1 synergy in regulating TRPM4 channel in mouse cardiomyocytes
by: Tao Ban, et al.
Published: (2024-12-01)

Development of novel osteoarthritis therapy by targeting AMPK-β-catenin-Runx2 signaling
by: Daofu Zeng, et al.
Published: (2025-01-01)

PRDM16 Enhances Osteoblastogenic RUNX2 via Canonical WNT10b/β-CATENIN Pathway in Testosterone-Treated Hypogonadal Men
by: Siresha Bathina, et al.
Published: (2025-01-01)

NOVEL RUNX1 VARIATION IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
by: Egzona Qipa, et al.
Published: (2023-06-01)

RUNX2 and ALP expression in osteoblast cells exposed by PMMA-HAp combination: An in vitro study
by: Claudia Michelle Darjanki, et al.
Published: (2023-03-01)

Custom exome panel revealed new mutations in MAPK14 and novel mutation in RUNX2 gene in patients with PCOS
by: Yunus Arikan, et al.
Published: (2025-01-01)

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
by: Jenna L. Carter, et al.
Published: (2025-01-01)

A novel RUNX2 splice site mutation in Chinese associated with cleidocranial dysplasia
by: Jing Wang, et al.
Published: (2024-11-01)

Transcription factor RUNX1 regulates coagulation factor XIII-A (F13A1): decreased platelet-megakaryocyte F13A1 expression and clot contraction in RUNX1 haplodeficiency
by: Fabiola Del Carpio-Cano, et al.
Published: (2025-01-01)

Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia
by: Xushu Zhong, et al.
Published: (2024-12-01)

Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia
by: Yu Cui, et al.
Published: (2024-12-01)

Novel biomarkers: the RUNX family as prognostic predictors in colorectal cancer
by: Yingting Liu, et al.
Published: (2024-12-01)

RUNX1 promotes proliferation of cervical cancer through TGFB2-MAPK pathway
by: Yongqin Jia, et al.
Published: (2025-01-01)

Venetoclax and Azacitidine Combination is an Effective Salvage Regimen for Fit Patients with IDH-2-mutated Acute Myeloid Leukemia Refractory to Conventional Induction Chemotherapy
by: Musa Fares Alzahrani
Published: (2024-12-01)

The effect of miR-205a with RUNX2 towards proliferation and differentiation of chicken chondrocytes in thiram-induced tibial dyschondroplasia
by: Yuxin Zhou, et al.
Published: (2024-12-01)

Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination
by: Daniela Taurino, et al.
Published: (2021-08-01)

Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center
by: Ziyi Hao, et al.
Published: (2024-12-01)

Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy
by: Cheng-Yu Tang, et al.
Published: (2023-10-01)

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
by: Yunshuo Xiao, et al.
Published: (2024-12-01)

Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases
by: Enrico Derenzini, et al.
Published: (2024-12-01)

Germline de novo alterations of RUNX1T1 in individuals with neurodevelopmental and congenital anomalies
by: Erfan Aref-Eshghi, et al.
Published: (2025-01-01)

miR-468-3p suppresses osteogenic differentiation of BMSCs by targeting Runx2 and inhibits bone formation
by: Tao Fang, et al.
Published: (2024-12-01)

First case of acute promyelocytic leukemia with TFG-RARA achieved complete remission treated with venetoclax and all-trans retinoic acid
by: Li Zhu, et al.
Published: (2024-12-01)

Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
by: Stefano Molica, et al.
Published: (2021-06-01)

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
by: Jingying Cui, et al.
Published: (2024-12-01)